AffaMed Therapeutics to merge with EverInsight Therapeutics.

AffaMed Therapeutics, a biopharmaceutical company, agreed to merge with EverInsight Therapeutics, a biopharmaceutical company focused on the development and commercialization of innovative drugs in ophthalmology, and neurological and psychiatric disorders in Greater China and globally. Financial terms were not disclosed. "“Under the leadership of Dr. Zhao alongside our high caliber management team with deep expertise in global biopharmaceutical development, AffaMed is poised to become the leading global company dedicated to therapeutics in ophthalmology, neurology and psychiatry based in China. We look forward to leveraging our combined R&D capabilities to advance this strong portfolio of therapeutic candidates as we work to create synergy and value for our shareholders," Wei Fu, EverInsight Therapeutics CEO.